Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.... Show more
Rating: Hold

Corbus Pharmaceuticals Financial Health

Profitability:0.06/10

Corbus Pharmaceuticals has worst Profitability than 100% of the companies on the Biotechnology industry

Net Margin: -1565.79%

Corbus Pharmaceuticals has worst Net Margin than 100% of the companies on the Biotechnology industry


ROE (Return on Equity): -86.05%

Corbus Pharmaceuticals has worst ROE (Return on Equity) than 95.24% of the companies on the Biotechnology industry


ROA (Return on Assets): -29.72%

Corbus Pharmaceuticals has worst ROA (Return on Assets) than 100% of the companies on the Biotechnology industry


Operating Efficiency:0.03/10

Corbus Pharmaceuticals has worst Operating Efficiency than 100% of the companies on the Biotechnology industry

Operating Margin: -1631.84%

Corbus Pharmaceuticals has worst Operating Margin than 100% of the companies on the Biotechnology industry


Liquidity:6.38/10

Corbus Pharmaceuticals has worst Liquidity than 95.24% of the companies on the Biotechnology industry

Quick Ratio: 2.06

Corbus Pharmaceuticals has worst Quick Ratio than 85.71% of the companies on the Biotechnology industry


Operating Cash Flow Ratio: -2.51

Corbus Pharmaceuticals has worst Operating Cash Flow Ratio than 90% of the companies on the Biotechnology industry


Solvency:4.46/10

Corbus Pharmaceuticals has worst Solvency than 85% of the companies on the Biotechnology industry

Debt to Equity Ratio: 0.9

Corbus Pharmaceuticals has worst Debt to Equity Ratio than 85% of the companies on the Biotechnology industry


Interest Coverage Ratio: -2.51

Corbus Pharmaceuticals has worst Interest Coverage Ratio than 90% of the companies on the Biotechnology industry


Corbus Pharmaceuticals revenue quarter by quarter
Corbus Pharmaceuticals operating expenses

👀 Get a summary of every week for free

Top company news, earnings report, analysis and more.

InspectCompany.com

We aim to help investors learn more about the companies in which they invest. We believe investing should be less about trying to find patterns in charts and more about investing in the companies that better represent your vision for the future.

Disclaimer: InspectCompany does not guarantee that any of the information available on our website, APIs or provided by any other means is complete, accurate, current, reliable or appropriate for your needs. Some of our information is provided by third party services and we cannot guarantee that is complete, accurate, current, reliable or appropriate for your needs. The information and recommendations on this site are for educational purposes only and should not be used to replace the advice of financial advisors and other professionals. All our services, information, data and/or recommendations are provided on an "as is" basis and without warranties of any kind, either express or implied. We do not guarantee that our services, information, data and/or recommendations are complete, accurate, current, reliable or appropriate for your needs.  Read more